111 related articles for article (PubMed ID: 35964360)
1. Efficacy of cationic amphiphilic antihistamines on outcomes of patients treated with immune checkpoint inhibitors.
Chiang CH; Chiang CH; Peng CY; Hsia YP; See XY; Horng CS; Chang YC; Shen XE; Wang SS; Tsai TC; Chen YJ; Ma KS; Chen BS; Luan YZ; Tay ST; Shen CH; Chung KC; Chiang CH; Peng CM
Eur J Cancer; 2022 Oct; 174():1-9. PubMed ID: 35964360
[TBL] [Abstract][Full Text] [Related]
2. The Efficacy of Cationic Amphiphilic Antihistamines on Outcomes of Patients with Pancreatic Ductal Adenocarcinoma.
Chiang CH; Chiang CH; Hsia YP; Chen BS; Jaroenlapnopparat A; Chiang CH; Peng CM
J Gastrointest Cancer; 2024 Mar; 55(1):175-177. PubMed ID: 37707624
[TBL] [Abstract][Full Text] [Related]
3. Impact of antihistamine use on the survival outcomes of immune checkpoint inhibitors in advanced cancer patients.
Eylemer Mocan E; Yekedüz E; Karataş G; Yazgan SC; Köksoy EB; Çay Şenler F; Utkan G; Demirkazik A; Akbulut H; Ürün Y
Anticancer Drugs; 2024 Feb; 35(2):190-194. PubMed ID: 38018837
[TBL] [Abstract][Full Text] [Related]
4. Effect of metformin on outcomes of patients treated with immune checkpoint inhibitors: a retrospective cohort study.
Chiang CH; Chen YJ; Chiang CH; Chen CY; Chang YC; Wang SS; See XY; Horng CS; Peng CY; Hsia YP; Peng CM; Chiang CH
Cancer Immunol Immunother; 2023 Jun; 72(6):1951-1956. PubMed ID: 36651967
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of antihistamines on mortality in patients receiving maintenance hemodialysis: an observational study using propensity score matching.
Omae K; Yoshikawa M; Sakura H; Nitta K; Ogawa T
Heart Vessels; 2017 Oct; 32(10):1195-1201. PubMed ID: 28509076
[TBL] [Abstract][Full Text] [Related]
6. The Effect of Renin-Angiotensin-Aldosterone System Inhibitors on Outcomes of Patients Treated with Immune Checkpoint Inhibitors: a Retrospective Cohort Study.
Chiang CH; Wang SS; Chang YC; Chiang CH; Chen CY; Chen YJ; See XY; Peng CY; Hsia YP; Chiang CH; Peng CM
Clin Oncol (R Coll Radiol); 2023 Jul; 35(7):446-453. PubMed ID: 36894383
[TBL] [Abstract][Full Text] [Related]
7. Repurposing Cationic Amphiphilic Antihistamines for Cancer Treatment.
Ellegaard AM; Dehlendorff C; Vind AC; Anand A; Cederkvist L; Petersen NHT; Nylandsted J; Stenvang J; Mellemgaard A; Østerlind K; Friis S; Jäättelä M
EBioMedicine; 2016 Jul; 9():130-139. PubMed ID: 27333030
[TBL] [Abstract][Full Text] [Related]
8. Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors.
Ma VT; Su CT; Hu M; Taylor JMG; Daignault-Newton S; Kellezi O; Dahl MN; Shah MA; Erickson S; Lora J; Hamasha R; Ali A; Yancey S; Kiros L; Balicki HM; Winfield DC; Green MD; Alva AS
Urol Oncol; 2021 Jul; 39(7):437.e1-437.e9. PubMed ID: 33495117
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of treatment satisfaction in children with allergic disease treated with an antihistamine: an international, non-interventional, retrospective study.
Ferrer M; Morais-Almeida M; Guizova M; Khanferyan R
Clin Drug Investig; 2010; 30(1):15-34. PubMed ID: 19995095
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of Lipophilic Statins on Outcomes of Patients Treated with Immune Checkpoint Inhibitors.
Chiang CH; Chen YJ; See XY; Chang YC; Wang SS; Peng CY; Horng CS; Hsia YP; Chiang CH; Peng CM; Chiang CH
Oncology; 2023; 101(9):537-541. PubMed ID: 37245500
[TBL] [Abstract][Full Text] [Related]
11. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
12. The efficacy of immune checkpoint inhibitors in advanced
Hu J; Huang D; Wang Y; Li D; Yang X; Fu Y; Du N; Zhao Y; Li X; Ma J; Hu Y
Front Immunol; 2022; 13():975246. PubMed ID: 36159795
[TBL] [Abstract][Full Text] [Related]
13. Health-related quality of life in cancer patients treated with immune checkpoint inhibitors in randomised controlled trials: A systematic review and meta-analysis.
Boutros A; Bruzzone M; Tanda ET; Croce E; Arecco L; Cecchi F; Pronzato P; Ceppi M; Lambertini M; Spagnolo F
Eur J Cancer; 2021 Dec; 159():154-166. PubMed ID: 34753012
[TBL] [Abstract][Full Text] [Related]
14. Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors - A systematic review and meta-analysis.
Hussaini S; Chehade R; Boldt RG; Raphael J; Blanchette P; Maleki Vareki S; Fernandes R
Cancer Treat Rev; 2021 Jan; 92():102134. PubMed ID: 33302134
[TBL] [Abstract][Full Text] [Related]
15. Survival benefit from immunocheckpoint inhibitors in stage IV non-small cell lung cancer patients with brain metastases: A National Cancer Database propensity-matched analysis.
Takamori S; Komiya T; Powell E
Cancer Med; 2021 Feb; 10(3):923-932. PubMed ID: 33340271
[TBL] [Abstract][Full Text] [Related]
16. Effect of cyclo-oxygenase inhibitor use during checkpoint blockade immunotherapy in patients with metastatic melanoma and non-small cell lung cancer.
Wang SJ; Khullar K; Kim S; Yegya-Raman N; Malhotra J; Groisberg R; Crayton SH; Silk AW; Nosher JL; Gentile MA; Mehnert JM; Jabbour SK
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33020239
[TBL] [Abstract][Full Text] [Related]
17. Association of prior fluoroquinolone treatment with survival outcomes of immune checkpoint inhibitors in Asia.
Lu PH; Tsai TC; Chang JW; Deng ST; Cheng CY
J Clin Pharm Ther; 2021 Apr; 46(2):408-414. PubMed ID: 33332621
[TBL] [Abstract][Full Text] [Related]
18. Desloratadine and loratadine stand out among common H
Fritz I; Wagner P; Broberg P; Einefors R; Olsson H
Acta Oncol; 2020 Sep; 59(9):1103-1109. PubMed ID: 32459128
[TBL] [Abstract][Full Text] [Related]
19. Antihistamines and Ovarian Cancer Survival: Nationwide Cohort Study and in Vitro Cell Viability Assay.
Verdoodt F; Dehlendorff C; Jäättelä M; Strauss R; Pottegård A; Hallas J; Friis S; Kjaer SK
J Natl Cancer Inst; 2020 Sep; 112(9):964-967. PubMed ID: 31688928
[TBL] [Abstract][Full Text] [Related]
20. Both combined or sequential use with immune checkpoint inhibitors on cetuximab-treated patients with recurrent or metastatic head and neck squamous cell carcinoma improve the overall survival.
Lien MY; Wang TH; Hsieh CY; Tsai MH; Hua CH; Cheng FM; Chung WH; Tang CH; Chia-Hsun Hsieh J
Oral Oncol; 2021 Aug; 119():105380. PubMed ID: 34146822
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
